UBS Group
ARCT icon

UBS Group’s Arcturus Therapeutics ARCT Stock Holding History

UBS Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,900
Closed -$367K – 10475
2025
Q3 		$367K Buy
+19,900
New +$320K ﹤0.01% 6307

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

UBS Group's ARCT Position: Q2 2026 in Review

UBS Group increased its Arcturus Therapeutics (ARCT) stake by 7.1% in Q2 2026, buying an estimated $255K and bringing the position to 490,632 shares worth $3.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4603.

UBS Group first reported a position in ARCT in Q4 2014 and has held it in 42 quarters since. The position peaked at $5.45M in Q1 2022. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • UBS Group held 490,632 shares of Arcturus Therapeutics worth $3.3M as of Q2 2026.
  • UBS Group bought 32,355 Arcturus Therapeutics shares in Q2 2026, an estimated $255K.
  • Arcturus Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4603 holding.
  • UBS Group first reported a position in Arcturus Therapeutics in Q4 2014 and has held it in 42 quarters since.
  • UBS Group's Arcturus Therapeutics position peaked at $5.45M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.